keyword
MENU ▼
Read by QxMD icon Read
search

CRVO

keyword
https://www.readbyqxmd.com/read/28639290/comparison-between-anti-vegf-therapy-and-corticosteroid-or-laser-therapy-for-macular-oedema-secondary-to-retinal-vein-occlusion-a-meta-analysis
#1
REVIEW
T Qian, M Zhao, X Xu
WHAT IS KNOWN AND OBJECTIVE: Therapeutic effects of anti-VEGF agents, corticosteroids and laser therapy have been previously examined for treating macular oedema secondary to branch and central retinal vein occlusion (BRVO and CRVO). However, anti-VEGF efficacy has not been previously compared to corticosteroid or laser therapy efficacy. We performed a meta-analysis to compare these treatments. METHODS: Pertinent publications were identified through comprehensive literature searches...
June 22, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28629694/interleukin-6-participation-in-pathology-of-ocular-diseases
#2
REVIEW
Forouhe Zahir-Jouzdani, Fatemeh Atyabi, Nazanin Mojtabavi
Interleukin-6 (IL-6) is a multifunctional cytokine that affects a variety of cells in the body such as osteoclasts, hepatocytes, endothelial cells, epithelial cells, white and red blood cells and etc. Elevated levels of IL-6 have been detected in many ocular diseases. Studies show that IL-6 has a major role in the pathology of glaucoma, CRVO, macular edema, ocular neovascularization, posterior capsule opacity formation, keratitis, dry eye disease, allergic eye disease, ocular autoimmune disease, corneal chemical burn, ocular inflammation and so on...
June 10, 2017: Pathophysiology: the Official Journal of the International Society for Pathophysiology
https://www.readbyqxmd.com/read/28620704/ranibizumab-versus-dexamethasone-implant-for-central-retinal-vein-occlusion-the-ranidex-study
#3
Irini Chatziralli, George Theodossiadis, Stamatina A Kabanarou, Efstratios Parikakis, Tina Xirou, Panagiotis Mitropoulos, Panagiotis Theodossiadis
PURPOSE: To compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). METHODS: Participants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab (n = 25) or intravitreal 0.7 mg dexamethasone implant (n = 17). The main outcomes included the mean change in best corrected visual acuity (BCVA) and central subfield thickness (CST) at month 12 compared to baseline in the two groups...
June 15, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28613222/laboratory-evaluation-of-hypercoagulable-states-in-patients-with-central-retinal-vein-occlusion-who-are-less-than-56-years-of-age
#4
Qingyun Liu, J Michael Lahey, Rachel Karlen, Jay M Stewart
PURPOSE: To investigate whether the results of early tests for hypercoagulability are correlated with the development of central retinal vein occlusion risk factors later in life and to evaluate the necessity of these tests in younger patients. METHODS: This was a retrospective, observational case series. From January 1995 to December 2014, 55 patients aged below 56 years with central retinal vein occlusion (CRVO) were enrolled in the study. Laboratory evaluations for homocysteine, activated protein C resistance, protein C activity, protein S activity, antithrombin III activity, antiphospholipid antibodies, and anticardiolipin antibodies were obtained at the onset of CRVO...
April 24, 2017: Retina
https://www.readbyqxmd.com/read/28605930/central-retinal-vein-occlusion-after-coronary-artery-bypass-surgery-a-case-report
#5
Ufuk Ciloglu, Mustafa Aldag, Sebnem Albeyoglu, Veysel Aykut, Canan Karakaya, Burcu Gonul
OBJECTIVE: The aim of this study is to report a case of central retinal vein occlusion (CRVO) after coronary artery bypass graft (CABG) surgery. In this report, we present the third case in the literature with CRVO after cardiopulmonary bypass (CPB), and the first case after CABG. CASE REPORT: A 59-year-old male patient complaining of chest pain was admitted to our hospital. The patient underwent an elective coronary angiography and was diagnosed with three-vessel coronary artery disease...
May 2017: Acta Medica Academica
https://www.readbyqxmd.com/read/28603574/central-retinal-vein-occlusion-in-younger-swedish-adults-case-reports-and-review-of-the-literature
#6
Elisabeth Wittström
PURPOSE: To investigate associated systemic diseases, other conditions, visual outcome, ocular complications and treatment in Swedish patients younger than 50 years with central retinal vein occlusion (CRVO) and reviewing the literature. METHODS: Twenty-two patients with CRVO, younger than 50 years, were examined with full-field electroretinography (ERG) within 3 months after a thrombotic event, or were periodically examined and were observed for at least 6 months...
2017: Open Ophthalmology Journal
https://www.readbyqxmd.com/read/28592811/evaluating-the-impact-of-vitreomacular-adhesion-on-anti-vegf-therapy-for-retinal-vein-occlusion-using-machine-learning
#7
Sebastian M Waldstein, Alessio Montuoro, Dominika Podkowinski, Ana-Maria Philip, Bianca S Gerendas, Hrvoje Bogunovic, Ursula Schmidt-Erfurth
Vitreomacular adhesion (VMA) represents a prognostic biomarker in the management of exudative macular disease using anti-vascular endothelial growth factor (VEGF) agents. However, manual evaluation of VMA in 3D optical coherence tomography (OCT) is laborious and data on its impact on therapy of retinal vein occlusion (RVO) are limited. The aim of this study was to (1) develop a fully automated segmentation algorithm for the posterior vitreous boundary and (2) to study the effect of VMA on anti-VEGF therapy for RVO...
June 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28591282/incidence-of-anterior-segment-neovascularization-during-intravitreal-treatment-for-macular-edema-secondary-to-central-retinal-vein-occlusion
#8
Luiz Filipe Adami Lucatto, Octaviano Magalhães-Junior, Juliana M B Prazeres, Adriano M Ferreira, Ramon A Oliveira, Nilva S Moraes, Flávio E Hirai, Mauricio Maia
Purpose: To analyze the effects of injections of intravitreal triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients with macular edema secondary to central retinal vein occlusion (CRVO). Methods: In this prospective, randomized, double-masked, sham-controlled study, 35 patients with macular edema following CRVO were randomized to intravitreal bevacizumab, intravitreal triamcinolone acetonide, or sham injections during the first 6 months of the study...
March 2017: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/28559717/serum-vitamin-d-levels-in-indian-patients-with-retinal-venous-occlusions
#9
Avadhesh Oli, D Joshi
PURPOSE: To estimate serum vitamin D (25 OH D) level in patients of retinal vein occlusion (RVO) and compare it with age-matched controls. METHODS AND MATERIAL: Forty patients above 18 years of age with retinal vein occlusion and forty age-matched controls underwent serum vitamin D (Vit D) level estimation using a standard protocol. Student's t test was used to analyse differences between the mean of two groups. RESULTS: The mean age in RVO and control group was 60...
April 2017: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/28503435/evaluation-of-hyperreflective-foci-as-a-prognostic-factor-of-visual-outcome-in-retinal-vein-occlusion
#10
Bin Mo, Hai-Ying Zhou, Xuan Jiao, Feng Zhang
AIM: To evaluate the potential role of hyperreflective foci (HF) as a prognostic indicator of visual outcome in patients with macular edema (ME) due to retinal vein occlusion (RVO). METHODS: We retrospectively reviewed 50 eyes of 50 patients with ME due to ischemic central retinal vein occlusion (CRVO), non-ischemic CRVO and branch retinal vein occlusion (BRVO) who were treated with anti-vascular endothelial growth factor (anti-VEGF) at Beijing Tongren Eye Center from January 2013 to July 2016...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28499055/sequential-sterile-intraocular-inflammation-associated-with-consecutive-intravitreal-injections-of-aflibercept-and-ranibizumab
#11
Dilraj S Grewal, Tayler Schwartz, Sharon Fekrat
The authors report the unique response of two patients treated for cystoid macular edema (CME) secondary to central retinal vein occlusion (CRVO) who developed sequential episodes of likely sterile inflammatory responses following separate intravitreal injections of aflibercept (Eylea; Regeneron, Tarrytown, NY) and ranibizumab (Lucentis; Genentech, South San Francisco, CA) despite multiple previous uneventful injections for CME secondary to CRVO. Following the twenty-fifth aflibercept and seventh ranibizumab injection, two patients developed an acute inflammatory response, which was treated empirically with intravitreal antibiotics and topical and oral steroids (in Case 2)...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28492860/baseline-factors-associated-with-6-month-visual-acuity-and-retinal-thickness-outcomes-in-patients-with-macular-edema-secondary-to-central-retinal-vein-occlusion-or-hemiretinal-vein-occlusion-score2-study-report-4
#12
RANDOMIZED CONTROLLED TRIAL
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Jacqueline King, Andrew N Antoszyk, Mark A Peters, Michael Tolentino
Importance: Macular edema (ME) is the leading cause of decreased visual acuity (VA) associated with retinal vein occlusion (RVO). Identifying factors associated with better outcomes in RVO eyes treated with anti-vascular endothelial growth factor (VEGF) therapy may provide information useful in counseling patients. Objective: To investigate baseline characteristics associated with 6-month VA and central subfield thickness (CST) outcomes in participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)...
June 1, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28475051/predicting-macular-edema-recurrence-from-spatio-temporal-signatures-in-optical-coherence-tomography-images
#13
Wolf-Dieter Vogl, Sebastian M Waldstein, Bianca S Gerendas, Ursula Schmidt-Erfurth, Georg Langs
Prediction of treatment responses from available data is key to optimizing personalized treatment. Retinal diseases are treated over long periods and patients' response patterns differ substantially, ranging from a complete response to a recurrence of the disease and need for re-treatment at different intervals. Linking observable variables in high-dimensional observations to outcome is challenging. In this paper, we present and evaluate two different data-driven machine learning approaches operating in a high-dimensional feature space: sparse logistic regression and Random Forests based extra trees (ET)...
May 2, 2017: IEEE Transactions on Medical Imaging
https://www.readbyqxmd.com/read/28473680/bilateral-central-retinal-vein-occlusion-in-a-pregnant-lady
#14
M A Loh, S Abirami, M F Chong
We report a rare case of central retinal vein occlusion (CRVO) in pregnancy. There was dramatic deterioration of vision in both eyes through pregnancy despite repeated attempts of laser treatment and systemically controlled diabetes. Significant improvement was noted postpartum. Pregnancy is an aggravated factor of bilateral CRVO.
April 2017: Medical Journal of Malaysia
https://www.readbyqxmd.com/read/28470332/retinal-oxygen-saturation-correlates-with-visual-acuity-but-does-not-predict-outcome-after-anti-vegf-treatment-in-central-retinal-vein-occlusion
#15
Signe Krejberg Jeppesen, Toke Bek
Purpose: Occlusion of the central retinal vein (CRVO) is a frequent cause of visual loss. The occlusion induces hypoxia in the retina and the larger retinal veins, but the significance of retinal oxygen saturation for visual acuity at diagnosis and after anti-VEGF treatment for CRVO has not been studied in detail. Methods: Retinal oximetry was performed in 91 patients consecutively referred for specialist evaluation of CRVO. The correlation between oxygen saturation in larger retinal vessels and visual acuity at the primary examination and the predictive value of oxygen saturation for visual prognosis after three monthly intravitreal injections with anti-VEGF medication were studied...
May 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28458584/anti-vegf-therapy-for-central-retinal-vein-occlusion-caused-by-tuberculosis-associated-uveitis-a-case-report
#16
Manzo Taguchi, Yutaka Sakurai, Takayuki Kanda, Masaru Takeuchi
BACKGROUND: Tuberculosis (TB)-associated uveitis presents periphlebitis, occasionally causing central retinal vascular occlusion (CRVO). Intravitreal injection of ranibizumab (IVR) is an effective treatment for CRVO, which improves macular edema (ME) by reducing vascular permeability and prevents progression of retinal nonperfusion in CRVO. We report a case of CRVO due to TB-associated uveitis, which initially remitted by repeated IVR as an adjunct to anti-TB therapy and systemic corticosteroids, but subsequently led to severe vitreous hemorrhage (VH)...
2017: International Medical Case Reports Journal
https://www.readbyqxmd.com/read/28437483/quantitative-microvascular-analysis-of-retinal-venous-occlusions-by-spectral-domain-optical-coherence-tomography-angiography
#17
Nicole Koulisis, Alice Y Kim, Zhongdi Chu, Anoush Shahidzadeh, Bruce Burkemper, Lisa C Olmos de Koo, Andrew A Moshfeghi, Hossein Ameri, Carmen A Puliafito, Veronica L Isozaki, Ruikang K Wang, Amir H Kashani
PURPOSE: To quantitatively evaluate the retinal microvasculature in human subjects with retinal venous occlusions (RVO) using optical coherence tomography angiography (OCTA). DESIGN: Retrospective, cross-sectional, observational case series. PARTICIPANTS: Sixty subjects (84 eyes) were included (20 BRVO, 14 CRVO, 24 unaffected fellow eyes, and 26 controls). METHODS: OCTA was performed on a prototype, spectral domain-OCTA system in the 3x3mm central macular region...
2017: PloS One
https://www.readbyqxmd.com/read/28427057/long-term-anatomical-and-functional-outcomes-in-patients-with-ischemic-central-retinal-vein-occlusion-treated-with-anti-vascular-endothelial-growth-factor-agents
#18
Irini Chatziralli, George Theodossiadis, Efstratios Parikakis, Panagiotis G Mitropoulos, Panagiotis Theodossiadis
PURPOSE: To evaluate the anatomical and functional outcomes in patients with ischemic central retinal vein occlusion (CRVO) treated with intravitreal anti-vascular endothelial growth factor (VEGF) agents. METHODS: This retrospective study included 15 treatment-naive patients with ischemic CRVO and macular edema who were treated with intravitreal ranibizumab or aflibercept. The main outcomes were the evolution of retinal ischemia over time, as well as the change in best corrected visual acuity (BCVA) and in central subfield thickness (CST) at month 24...
April 21, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28405787/outcomes-of-switching-treatment-to-aflibercept-in-patients-with-macular-oedema-secondary-to-central-retinal-vein-occlusion-refractory-to-ranibizumab
#19
Vasileios Konidaris, Zahra Al-Hubeshy, Konstantinos T Tsaousis, Konstantina Gorgoli, Somnath Banerjee, Theodoros Empeslidis
PURPOSE: To assess the treatment outcome of switching from ranibizumab to aflibercept intravitreal injections in patients with macular oedema secondary to central retinal vein occlusion (CRVO). METHODS: A prospective interventional study was conducted in a tertiary retina service in Leicester Royal Infirmary, UK, where patients with CRVO and associated macular oedema were recruited. First-line treatment involved three monthly ranibizumab injections. Non-responders were defined as patients who despite a minimum of three consecutive injections had persistent intraretinal fluid one month after the last injection...
April 12, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28375791/intravitreal-dexamethasone-implant-for-treatment-of-serous-macular-detachment-in-central-retinal-vein-occlusion
#20
Ahmet Elbay, Hakan Ozdemir, Arif Koytak, Arif Melikov
PURPOSE: To evaluate the effect of intravitreal dexamethasone implant (Ozurdex) treatment on serous macular detachment (SMD) in patients with nonischemic central retinal vein occlusion (CRVO). METHODS: Retrospective, interventional, noncomparative case series was conducted. Twenty-four eyes of 24 patients with macular edema (ME) and SMD secondary to nonischemic CRVO made up the study population. Patients who had received intravitreal triamcinolone and/or antivascular endothelial growth factor treatment and/or had undergone retinal photocoagulation were excluded from the study...
July 2017: Journal of Ocular Pharmacology and Therapeutics
keyword
keyword
44183
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"